-+ 0.00%
-+ 0.00%
-+ 0.00%

Antengene says Australia HREC clears Phase 1 ATTRACT trial of ATG-201 in B-cell autoimmune diseases

PUBT·08/24/2026 22:42:45
Listen to the news
Antengene says Australia HREC clears Phase 1 ATTRACT trial of ATG-201 in B-cell autoimmune diseases
  • Antengene secured Australian HREC clearance for its Phase 1 ATTRACT trial of ATG-201 in B-cell-mediated autoimmune diseases.
  • The company also completed the Clinical Trial Notification filing with Australia’s TGA, enabling trial initiation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260825-12297330), on August 24, 2026, and is solely responsible for the information contained therein.